CCL

Összesen 52 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM067415
035-os BibID:(WoS)000392425200005 (Scopus)84991585385
Első szerző:Agca, R.
Cím:EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders : 2015/2016 update / R. Agca, S. C. Heslinga, S. Rollefstad, M. Heslinga, I. B. McInnes, M. J. L. Peters, T. K. Kvien, M. Dougados, H. Radner, F. Atzeni, J. Primdahl, A. Södergren, S. Wallberg Jonsson, J. van Rompay, C. Zabalan, T. R. Pedersen, L. Jacobsson, K. de Vlam, M. A. Gonzalez-Gay, A. G. Semb, G. D. Kitas, Y. M. Smulders, Z. Szekanecz, N. Sattar, D. P. M. Symmons, M. T. Nurmohamed
Dátum:2017
ISSN:0003-4967
Megjegyzések:Patients with rheumatoid arthritis (RA) and other inflammatory joint disorders (IJD) have increased cardiovascular disease (CVD) risk compared with the general population. In 2009, the European League Against Rheumatism (EULAR) taskforce recommended screening, identification of CVD risk factors and CVD risk management largely based on expert opinion. In view of substantial new evidence, an update was conducted with the aim of producing CVD risk management recommendations for patients with IJD that now incorporates an increasing evidence base. A multidisciplinary steering committee (representing 13 European countries) comprised 26 members including patient representatives, rheumatologists, cardiologists, internists, epidemiologists, a health professional and fellows. Systematic literature searches were performed and evidence was categorised according to standard guidelines. The evidence was discussed and summarised by the experts in the course of a consensus finding and voting process. Three overarching principles were defined. First, there is a higher risk for CVD in patients with RA, and this may also apply to ankylosing spondylitis and psoriatic arthritis. Second, the rheumatologist is responsible for CVD risk management in patients with IJD. Third, the use of non-steroidal anti-inflammatory drugs and corticosteroids should be in accordance with treatment-specific recommendations from EULAR and Assessment of Spondyloarthritis International Society. Ten recommendations were defined, of which one is new and six were changed compared with the 2009 recommendations. Each designated an appropriate evidence support level. The present update extends on the evidence that CVD risk in the whole spectrum of IJD is increased. This underscores the need for CVD risk management in these patients. These recommendations are defined to provide assistance in CVD risk management in IJD, based on expert opinion and scientific evidence.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Annals Of The Rheumatic Diseases. - 76 : 1 (2017), p. 17-28. -
További szerzők:Heslinga, S. C. Rollefstad, S. Heslinga, M. McInnes, I. B. Peters, M. J. L. Kvien, Tore K. Dougados, Maxime Radner, H. Atzeni, F. Primdahl, Jette Södergren, A. Wallberg Jonsson, S. van Rompay, J. Zabalan, C. Pedersen, T. R. Jacobsson, L. de Vlam, K. Gonzalez-Gay, Miguel A. Semb, Anne Grete Kitas, George Smulders, Yvo M. Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Sattar, Naveed Symmons, D. P. M. Nurmohamed, Michael T.
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

2.

001-es BibID:BIBFORM113899
035-os BibID:(WoS)001042183300001 (Scopus)85168274077
Első szerző:Almayali, Abdullah Ali Hadi
Cím:Three-month tapering and discontinuation of long- term, low-dose glucocorticoids in senior patients with rheumatoid arthritis is feasible and safe : placebo-controlled double blind tapering after the GLORIA trial / Abdullah Ali Hadi Almayali, Maarten Boers, Linda Hartman, Daniela Opris, Reinhard Bos, Marc R. Kok, Jose A. P. Da Silva, Ed Griep, Ruth Klaasen, Cornelia F. Allaart, Paul Baudoin, Hennie G. Raterman, Zoltan Szekanecz, Frank Buttgereit, Pavol Masaryk, Willem Lems, Yvo Smulders, Maurizio Cutolo, Marieke M. ter Wee
Dátum:2023
ISSN:0003-4967
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Annals Of The Rheumatic Diseases. - 82 : 10 (2023), p. 1307-1314. -
További szerzők:Boers, Maarten Hartman, Linda Opris, Daniela (1976-) (reumatológus) Bos, Reinhard Kok, Marc R. Da Silva, Jose A. P. Griep, Eduard N. Klaasen, Ruth Allaart, Cornelia F. Baudoin, Paul Raterman, Hennie G. Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Buttgereit, Frank Masaryk, Pavol Lems, Willem F. Smulders, Yvo M. Cutolo, Maurizio ter Wee, Marieke M.
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

3.

001-es BibID:BIBFORM016576
035-os BibID:WOS:000278017700038
Első szerző:Amital, Howard
Cím:Serum concentrations of 25-OH vitamin D in patients with systemic lupus erythematosus (SLE) are inversely related to disease activity : is it time to routinely supplement patients with SLE with vitamin D? / Amital, H., Szekanecz, Z., Szucs, G., Danko, K., Nagy, E., Csepany, T., Kiss, E., Rovensky, J., Tuchynova, A., Kozakova, D., Doria, A., Corocher, N., Agmon-Levin, N., Barak, V., Orbach, H., Zandman-Goddard, G., Shoenfeld, Y.
Dátum:2010
ISSN:0003-4967
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
külföldön készült közlemény
Megjelenés:Annals Of The Rheumatic Diseases. - 69 : 6 (2010), p. 1155-1157. -
További szerzők:Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Szűcs Gabriella (1963-) (belgyógyász, allergológus és klinikai immunológus, reumatológus) Dankó Katalin (1952-2021) (belgyógyász, allergológus és klinikai immunológus) Nagy Endre V. (1957-) (belgyógyász, endokrinológus) Csépány Tünde (1956-) (neurológus, pszichiáter) Kiss E. (Budapest) Rovensky, Josef Tuchynova, Alena Kozakova, D. Doria, Andrea Corocher, Nadia Agmon-Levin, Nancy Barak, Vivian Orbach, Hedi Zandman-Goddard, Gisele Shoenfeld, Yehuda
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

4.

001-es BibID:BIBFORM055349
Első szerző:Avouac, Jérôme
Cím:Joint and tendon involvement predict disease progression in systemic sclerosis : a EUSTAR prospective study / Jérôme Avouac, Ulrich A. Walker, Eric Hachulla, Gabriela Riemekasten, Giovanna Cuomo, Patricia E. Carreira, Paola Caramaschi, Lidia P. Ananieva, Marco Matucci-Cerinic, Laszlo Czirjak, Christopher Denton, Ulf Müller Ladner, Yannick Allanore, EUSTAR collaborators
Dátum:2014
ISSN:0003-4967
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
systemic sclerosis
Megjelenés:Annals of The Rheumatic Diseases 0 (2014), p. 1-7. -
További szerzők:Walker, Ulrich Hachulla, Eric Riemekasten, Gabriela Cuomo, Giovanna Carreira, Patricia E. Caramaschi, Paola Ananieva, Lidia P. Matucci-Cerinic, Marco Czirják László Denton, Christopher Ladner, Ulf Müller Allanore, Yannick Szűcs Gabriella (1963-) (belgyógyász, allergológus és klinikai immunológus, reumatológus) Szamosi Szilvia (1975-) (belgyógyász, reumatológus) EUSTAR
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

5.

001-es BibID:BIBFORM085928
Első szerző:Balogh Emese (reumatológus)
Cím:Effects of Anti-TNF Therapy on Markers of Angiogenesis and Vascular Pathology in Arthritis : a Comparative Approach / Balogh E., Végh E., Kerekes G., Váncsa A., Csomor P., Pogácsás L., Balázs F., McCormick J., Biniecka M.; Szántó S., Szücs G., Nagy Z., Fearon U., Veale D., Szekanecz Z.
Dátum:2015
ISSN:0003-4967
Tárgyszavak:Orvostudományok Elméleti orvostudományok idézhető absztrakt
folyóiratcikk
Megjelenés:Annals Of The Rheumatic Diseases. - 74 : Suppl. 2 (2015), p. 210. -
További szerzők:Végh Edit (1978-) (reumatológus, belgyógyász) Kerekes György (1973-) (belgyógyász, kardiológus, angiológus) Váncsa Andrea (1972-) (orvos) Csomor Péter (1984-) (biotechnológus) Pogácsás Lilla Balázs Fruzsina McCormick, Jennifer Biniecka, Monika Szántó Sándor (1968-) (belgyógyász, reumatológus) Szűcs Gabriella (1963-) (belgyógyász, allergológus és klinikai immunológus, reumatológus) Nagy Zsófia Fearon, Ursula Veale, Douglas J. Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus)
Internet cím:DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

6.

001-es BibID:BIBFORM055360
Első szerző:Balogh E.
Cím:Effects of anti-TNF therapy on markers of angiogenesis and vascular disease in rheumatoid arthritis : a comparative approach / E. Balogh, E. Vegh, G. Kerekes, A. Vancsa, P. Csomor, L. Pogacsas, F. Balazs, J. McCormick, M. Biniecka, S. Szanto, G. Szucs, U. Fearon, D. J. Veale, Z. Szekanecz
Dátum:2014
ISSN:0003-4967
Tárgyszavak:Orvostudományok Klinikai orvostudományok idézhető absztrakt
Megjelenés:Annals of The Rheumatic Diseases. - 73 : Suppl. 2 (2014), p. 855. -
További szerzők:Végh Edit (1978-) (reumatológus, belgyógyász) Kerekes György (1973-) (belgyógyász, kardiológus, angiológus) Váncsa Andrea (1972-) (orvos) Csomor Péter (1984-) (biotechnológus) Pogácsás Lilla Balázs F. McCormick, Jennifer Biniecka, Monika Szántó Sándor (1968-) (belgyógyász, reumatológus) Szűcs Gabriella (1963-) (belgyógyász, allergológus és klinikai immunológus, reumatológus) Fearon, Ursula Veale, Douglas J. Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

7.

001-es BibID:BIBFORM102565
035-os BibID:(cikkazonosító)222253 (WOS)000857901500028 (Scopus)85132447832
Első szerző:Bennett, Sarah E.
Cím:Assessing acceptability and identifying barriers and facilitators to implementation of the EULAR recommendations for patient education in inflammatory arthritis : a mixed-methods study with rheumatology professionals in 23 European and Asian countries / Sarah E. Bennett, Heidi A. Zangi, Ingrid Larsson, Catherine Beauvais, Carina Boström, Andrea Domján, Yvonne van Eijk-Hustings, Kristien Van der Elst, Françoise Fayet, Ricardo J. O. Ferreira, Mie Fusama, Mariela Geneva-Popova, María del Carmen Herrero Manso, Kirsten Hoeper, Bethan Jones, Marja Leena Kukkurainen, Suet Kei Gladys Kwok, Patricia Minnock, Tiziana Nava, Jette Primdahl, Roopa Rawat, Matylda Sierakowska, Michaela Stoffer-Marx, Astrid van Tubergen, Mwidimi Ndosi
Dátum:2022
ISSN:0003-4967
Megjegyzések:Objectives To disseminate and assess the level of acceptability and applicability of the European Alliance of Associations for Rheumatology (EULAR) recommendations for patient education among professionals in rheumatology across Europe and three Asian countries and identify potential barriers and facilitators to their application. Methods A parallel convergent mixed-methods design with an inductive approach was used. A web-based survey, available in 20 different languages, was distributed to health professionals by non-probability sampling. The level of agreement and applicability of each recommendation was assessed by (0?10) rating scales. Barriers and facilitators to implementation were assessed using free-text responses. Quantitative data were analysed descriptively and qualitative data by content analysis and presented in 16 categories supported by quotes. Results A total of 1159 completed the survey; 852 (73.5%) were women. Most of the professionals were nurses (n=487), rheumatologists (n=320), physiotherapists (n=158). For all recommendations, the level of agreement was high but applicability was lower. The four most common barriers to application were lack of time, lack of training in how to provide patient education, not having enough staff to perform this task and lack of evaluation tools. The most common facilitators were tailoring patient education to individual patients, using group education, linking patient education with diagnosis and treatment and inviting patients to provide feedback on patient education delivery. Conclusions This project has disseminated the EULAR recommendations for patient education to health professionals across 23 countries. Potential barriers to their application were identified and some are amenable to change, namely training patient education providers and developing evaluation tools.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Annals Of The Rheumatic Diseases. - 81 : 10 (2022), p. 1348-1357. -
További szerzők:Zangi, Heidi A. Larsson, Ingrid Beauvais, Catherine Boström, Carina Domján Andrea (1979-) (reumatológus) Eijk-Hustings, Yvonne van Elst, Kristien Van der Fayet, Françoise Ferreira, Ricardo J. O. Fusama, Mie Geneva-Popova, Mariela Herrero Manso, María del Carmen Hoeper, Kirsten Jones, Bethan Kukkurainen, Marja Leena Gladys Kwok, Suet Kei Minnock, Patricia Nava, Tiziana Primdahl, Jette Rawat, Roopa Sierakowska, Matylda Stoffer-Marx, Michaela Tubergen, Astrid van Ndosi, Mwidimi
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

8.

001-es BibID:BIBFORM102302
035-os BibID:(WOS)000805325600001 (Scopus)85132198667
Első szerző:Boers, Maarten
Cím:Low dose, add-on prednisolone in patients with rheumatoid arthritis aged 65+ : the pragmatic randomised, double-blind placebo-controlled GLORIA trial / Maarten Boers, Linda Hartman, Daniela Opris-Belinski, Reinhard Bos, Marc R. Kok, Jose A. P. Da Silva, Eduard N. Griep, Ruth Klaasen, Cornelia F. Allaart, Paul Baudoin, Hennie G. Raterman, Zoltan Szekanecz, Frank Buttgereit, Pavol Masaryk, L. Thomas Klausch, Sabrina Paolino, Annemarie M. Schilder, Willem F. Lems, Maurizio Cutolo, GLORIA Trial consortium
Dátum:2022
ISSN:0003-4967
Megjegyzések:Background Low-dose glucocorticoid (GC) therapy is widely used in rheumatoid arthritis (RA) but the balance of benefit and harm is still unclear. Methods The GLORIA (Glucocorticoid LOw-dose in RheumatoId Arthritis) pragmatic double-blind randomised trial compared 2 years of prednisolone, 5 mg/day, to placebo in patients aged 65+ with active RA. We allowed all cotreatments except long-term open label GC and minimised exclusion criteria, tailored to seniors. Benefit outcomes included disease activity (disease activity score; DAS28, coprimary) and joint damage (Sharp/van der Heijde, secondary). The other coprimary outcome was harm, expressed as the proportion of patients with ?1 adverse event (AE) of special interest. Such events comprised serious events, GC-specific events and those causing study discontinuation. Longitudinal models analysed the data, with one-sided testing and 95% confidence limits (95% CL). Results We randomised 451 patients with established RA and mean 2.1 comorbidities, age 72, disease duration 11 years and DAS28 4.5. 79% were on disease-modifying treatment, including 14% on biologics. 63% prednisolone versus 61% placebo patients completed the trial. Discontinuations were for AE (both, 14%), active disease (3 vs 4%) and for other (including covid pandemic-related disease) reasons (19 vs 21%); mean time in study was 19 months. Disease activity was 0.37 points lower on prednisolone (95% CL 0.23, p<0.0001); joint damage progression was 1.7 points lower (95% CL 0.7, p=0.003). 60% versus 49% of patients experienced the harm outcome, adjusted relative risk 1.24 (95% CL 1.04, p=0.02), with the largest contrast in (mostly non-severe) infections. Other GC-specific events were rare. Conclusion Add-on low-dose prednisolone has beneficial long-term effects in senior patients with established RA, with a trade-off of 24% increase in patients with mostly non-severe AE; this suggests a favourable balance of benefit and harm.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Annals Of The Rheumatic Diseases. - 81 : 7 (2022), p. 925-936. -
További szerzők:Hartman, Linda Opris, Daniela (1976-) (reumatológus) Bos, Reinhard Kok, Marc R. Da Silva, Jose A. P. Griep, Eduard N. Klaasen, Ruth Allaart, Cornelia F. Baudoin, Paul Raterman, Hennie G. Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Buttgereit, Frank Masaryk, Pavol Klausch, Thomas Paolino, Sabrina Schilder, Annemarie M. Lems, Willem F. Cutolo, Maurizio GLORIA Trial consortium
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

9.

001-es BibID:BIBFORM103789
035-os BibID:(WOS)000859802100001 (Scopus)85139865478
Első szerző:Charles-Schoeman, Christina
Cím:Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease : a post hoc analysis from ORAL Surveillance / Christina Charles-Schoeman, Maya H. Buch, Maxime Dougados, Deepak L. Bhatt, Jon T. Giles, Steven R. Ytterberg, Gary G. Koch, Ivana Vranic, Joseph Wu, Cunshan Wang, Kenneth Kwok, Sujatha Menon, Jose L. Rivas, Arne Yndestad, Carol A. Connell, Zoltan Szekanecz
Dátum:2022
ISSN:0003-4967
Megjegyzések:Objectives Evaluate risk of major adverse cardiovascular events (MACE) with tofacitinib versus tumour necrosis factor inhibitors (TNFi) in patients with rheumatoid arthritis (RA) with or without a history of atherosclerotic cardiovascular disease (ASCVD) in ORAL Surveillance. Methods Patients with RA aged >= 50 years with >= 1 additional CV risk factor received tofacitinib 5 mg or 10 mg two times per day or TNFi. Hazard rations (HRs) were evaluated for the overall population and by history of ASCVD (exploratory analysis). Results Risk of MACE, myocardial infarction and sudden cardiac death were increased with tofacitinib versus TNFi in ORAL Surveillance. In patients with history of ASCVD (14.7%; 640/4362), MACE incidence was higher with tofacitinib 5 mg two times per day (8.3%; 17/204) and 10 mg two times per day (7.7%; 17/222) versus TNFi (4.2%; 9/214). HR (combined tofacitinib doses vs TNFi) was 1.98 (95% confidence interval (CI) 0.95 to 4.14; interaction p values: 0.196 (for HR)/0.059 (for incidence rate difference)). In patients without history of ASCVD, MACE HRs for tofacitinib 5 mg two times per day (2.4%; 30/1251) and 10 mg two times per day (2.8%; 34/1234) versus TNFi (2.3%; 28/1237) were, respectively, 1.03 (0.62 to 1.73) and 1.25 (0.76 to 2.07). Conclusions This post hoc analysis observed higher MACE risk with tofacitinib versus TNFi in patients with RA and history of ASCVD. Among patients without history of ASCVD, all with prevalent CV risk factors, MACE risk did not appear different with tofacitinib 5 mg two times per day versus TNFi. Due to the exploratory nature of this analysis and low statistical power, we cannot exclude differential MACE risk for tofacitinib 5 mg two times per day versus TNFi among patients without history of ASCVD, but any absolute risk excess is likely low.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Antirheumatic Agents
Arthritis
Rheumatoid
Cardiovascular Diseases
Therapeutics
Megjelenés:Annals Of The Rheumatic Diseases. - 82 : 1 (2022), p. 119-129. -
További szerzők:Buch, Maya H. Dougados, Maxime Bhatt, Deepak L. Giles, Jon T. Ytterberg, Steven R. Koch, Gary G. Vranic, Ivana Wu, Joseph Wang, Cunshan Kwok, Kenneth Menon, Sujatha Rivas, Jose L. Yndestad, Arne Connell, Carol A. Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

10.

001-es BibID:BIBFORM067427
035-os BibID:(WoS)000401138800008 (Scopus)85007256365
Első szerző:Combe, Bernard
Cím:2016 update of the EULAR recommendations for the management of early arthritis / Bernard Combe, Robert Landewe, Claire I. Daien, Charlotte Hua, Daniel Aletaha, Jose María Álvaro-Gracia, Margôt Bakkers, Nina Brodin, Gerd R. Burmester, Catalin Codreanu, Richard Conway, Maxime Dougados, Paul Emery, Gianfranco Ferraccioli, Joao Fonseca, Karim Raza, Lucía Silva-Fernández, Josef S. Smolen, Diana Skingle, Zoltan Szekanecz, Tore K. Kvien, Annette van der Helm-van Mil, Ronald van Vollenhoven
Dátum:2017
ISSN:0003-4967
Megjegyzések:Objectives Since the 2007 recommendations for the management of early arthritis have been presented, considerable research has been published in the field of early arthritis, mandating an update of the 2007 European League Against Rheumatism (EULAR) recommendations for management of early arthritis.Methods In accordance with the 2014 EULAR Standardised Operating Procedures, the expert committee pursued an approach that was based on evidence in the literature and on expert opinion. The committee involved 20 rheumatologists, 2 patients and 1 healthcare professional representing 12 European countries. The group defined the focus of the expert committee and target population, formulated a definition of ♭management' and selected the research questions. A systematic literature research (SLR) was performed by two fellows with the help of a skilled librarian. A set of draft recommendations was proposed on the basis of the research questions and the results of the SLR. For each recommendation, the categories of evidence were identified, the strength of recommendations was derived and the level of agreement was determined through a voting process.Results The updated recommendations comprise 3 overarching principles and 12 recommendations for managing early arthritis. The selected statements involve the recognition of arthritis, referral, diagnosis, prognostication, treatment (information, education, pharmacological and non-pharmacological interventions), monitoring and strategy. Eighteen items were identified as relevant for future research.Conclusions These recommendations provide rheumatologists, general practitioners, healthcare professionals, patients and other stakeholders with an updated EULAR consensus on the entire management of early arthritis.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Annals Of The Rheumatic Diseases. - 76 : 6 (2017), p. 948-959. -
További szerzők:Landewé, Robert Daien, Claire I. Hua, Charlotte Aletaha, Daniel Álvaro-Gracia, Jose María Bakkers, Margôt Brodin, Nina Burmester, Gerd R. Codreanu, Catalin Conway, Richard Dougados, Maxime Emery, Paul Ferraccioli, Gianfranco Fonseca, João Raza, Karim Silva-Fernández, Lucía Smolen, Josef S. Skingle, Diana Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Kvien, Tore K. van der Helm-van Mil, Annette van Vollenhoven, Ronald
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

11.

001-es BibID:BIBFORM007056
Első szerző:Czirják László
Cím:Survival and causes of death in 366 Hungarian patients with systemic sclerosis / Czirjak, L., Kumanovics, G., Varju, C., Nagy, Z., Pakozdi, A., Szekanecz, Z., Szucs, G.
Dátum:2008
ISSN:1468-2060 (Electronic)
Megjegyzések:Survival analysis of a series of 366 consecutive patients with systemic sclerosis (SSc). METHODS: Clinical and laboratory data were evaluated from 1983 until 2005 using a standard protocol. The female/male ratio was 315/51. The mean (SD) age of the patients was 56.8 (12.2) years. The duration of disease was 12 (5-19) years with a median follow-up of 6 (3-12) years. RESULTS: Kaplan-Meier univariate analysis showed that renal, cardiac involvement, pigmentation disturbances, malabsorption, a forced vital capacity <50%, diffuse scleroderma, presence of early malignancy, anaemia, and increased erythrocyte sedimentation rate (ESR) were signs of unfavourable prognosis, whereas anti-centromere antibodies were indicators of a good survival. In the multivariate Cox proportional hazards model the presence of diffuse scleroderma, renal involvement, coexistence of a malignant disease, and increased ESR were poor independent prognostic signs. Elderly age at the onset of disease also caused an unfavourable outcome. A total of 86 SSc-related deaths were recorded during the follow-up. Of them, 65% were attributed to cardiorespiratory manifestation of disease. Tumour associated early death was found in 12 cases (14%). CONCLUSIONS: In addition to the well-known factors influencing the outcome (diffuse subset, internal organ involvements, and inflammatory signs), the coexistence of scleroderma with a malignancy also causes a poor outcome.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Adult
Age Factors
Aged
Autoantibodies/blood
Blood Sedimentation
Cause of Death
Centromere
Female
Heart Diseases
Humans
Kidney Diseases
Male
Middle Aged
Neoplasms
Prognosis
Proportional Hazards Models
Prospective Studies
Scleroderma, Systemic
Survival Analysis
Megjelenés:Annals of the Rheumatic Diseases. - 67 : 1 (2008), p. 59-63. -
További szerzők:Kumánovics Gábor Varjú Cecília Nagy Zoltán (orvos) Pákozdi Angéla Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Szűcs Gabriella (1963-) (belgyógyász, allergológus és klinikai immunológus, reumatológus)
Internet cím:elektronikus változat
elektronikus változat
Borító:

12.

001-es BibID:BIBFORM112646
035-os BibID:(WOS)000413181404661
Első szerző:Domján Andrea (reumatológus)
Cím:The role of patient support programmes in health literacy of patients. Results of a 1.5-year-long Hungarian study / A. Domján, Z. Szekanecz, J. Pilling, Gy. Purebl, Z. Szabo, P. Kakuk
Dátum:2017
ISSN:0003-4967
Tárgyszavak:Orvostudományok Egészségtudományok idézhető absztrakt
folyóiratcikk
patient support programmes
Megjelenés:Annals of the Rheumatic Diseases. - 76 : Suppl_2 (2017), p. 1548. -
További szerzők:Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Pilling János Purebl György Szabó Zoltán (1970-) (belgyógyász, reumatológus) Kakuk Péter (1973-) (filozófus)
Internet cím:DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Rekordok letöltése1 2 3 4 5 
Corvina könyvtári katalógus v8.2.27 © 2023 Monguz kft. Minden jog fenntartva.